Evidence map›Paper›PMID 24916542›Full record

ArticleJournal of Alzheimer's disease : JAD2014

Combining select neuropsychological assessment with blood-based biomarkers to detect mild Alzheimer's disease: a molecular neuropsychology approach.

Melissa Edwards, Valerie Hobson Balldin, James Hall, Sid O'Bryant

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2016
    Review
  6. Molecular markers of neuropsychological functioning and Alzheimer's disease.Alzheimer's & dementia (Amsterdam, Netherlands) · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Melissa EdwardsDepartment of Psychology, University of North Texas, Denton, TX, USA.
Valerie Hobson BalldinDepartment of Psychology, South Texas Veterans Health Care System, San Antonio, TX, USA.
James HallDepartment of Psychiatry, University of North Texas Health Science Center, Fort Worth, TX, USA Institute for Aging & Alzheimer's Disease Research, University of North Texas Health Science Center, Fort Worth, TX, USA.
Sid O'BryantInstitute for Aging & Alzheimer's Disease Research, University of North Texas Health Science Center, Fort Worth, TX, USA Department of Internal Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA.
University of North Texas · USSouth Texas Veterans Health Care System · USUniversity of North Texas Health Science Center · US

Funding

ROLE OF GLUTAMATE IN ALZHEIMER'S DISEASEP30AG012300 · NIA · UT SOUTHWESTERN MEDICAL CENTER · PI ROSENBERG, ROGER NEWMAN · 1994 to 2016
$26.6M
A Blood-Based Screening Tool for Alzheimer's DiseaseR01AG039389 · NIA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI O'BRYANT, SID E · 2012 to 2013
$608k
NIA NIH HHS P30 AG012300NIA NIH HHS P30AG12300NIA NIH HHS R01 AG039389NIA NIH HHS R01AG039389
6 · The paper itself

Abstract

backgroundCurrent work has sought to establish a rapid and cost effective means of screening for Alzheimer's disease (AD) with the most recent findings showing utility of integrating blood-based biomarkers with cognitive measures.

objectiveThe current project sought to create a combined biomarker-cognitive profile to detect mild AD.

methodsData was analyzed from 266 participants (129 AD cases [Early AD n = 93; Very Early AD n = 36]; 137 controls) enrolled in the Texas Alzheimer's Research and Care Consortium (TARCC). Non-fasting serum samples were collected from each participant and assayed via a multi-plex biomarker assay platform using electrochemiluminescence. Logistic Regression was utilized to detect early AD using two serum biomarkers (TNFα and IL7), demographic information (age), and one neuropsychological measure (Clock 4-point) as predictor variable. Disease severity was determined via Clinical Dementia Rating (CDR) scale global scores.

resultsIn the total sample (all levels of CDR scores), the combination of biomarkers, cognitive test score, and demographics yielded the obtained sensitivity (SN) of 0.94, specificity (SP) of 0.90, and an overall accuracy of 0.92. When examining early AD cases (i.e.m CDR = 0.5-1), the biomarker-cognitive profile yielded SN of 0.94, SP of 0.85, and an overall accuracy of 0.91. When restricted to very early AD cases (i.e., CDR = 0.5), the biomarker-cognitive profile yielded SN of 0.97 and SP of 0.72, with an overall accuracy of 0.91.

conclusionsThe combination of demographics, two biomarkers, and one cognitive test created a biomarker-cognitive profile that was highly accurate in detecting the presence of AD, even in the very early stages.

Indexed as

Alzheimer DiseaseNeuropsychological TestsAgedAged, 80 and overBiomarkersCognition DisordersFemaleHumansLogistic ModelsMalePsychiatric Status Rating ScalesSensitivity and SpecificityBiomarkersAlzheimer's diseasebiomarkersmolecularneuropsychology

Identifiers

PMID24916542
PMCPMC4416413
OpenAlexW1667783706

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.